Novel Cardiovascular Biomarkers in Patients With Kidney Disease

Launched by LIVERPOOL UNIVERSITY HOSPITALS NHS FOUNDATION TRUST · Sep 7, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how certain markers in the blood can help doctors find heart problems in patients with kidney disease, particularly those on haemodialysis (HD). Haemodialysis is a treatment that helps people with severe kidney failure by filtering waste from their blood, but it can put a lot of stress on the heart. The researchers will look at how proteins and fats in the blood change in HD patients compared to those on peritoneal dialysis (PD) or those with early-stage kidney disease. By studying these changes, they hope to identify which patients are at higher risk for serious heart issues.

To participate in this trial, individuals must be at least 45 years old, or 18 with a history of diabetes. They should be starting haemodialysis for the first time, or they can be in the comparison group if they are on peritoneal dialysis or have earlier-stage kidney disease with high blood pressure. Participants will need to understand the study's purpose and provide their consent. It's important to note that patients with existing heart disease or active cancer will not be included in this study. If you're eligible and decide to join, you’ll contribute to important research that could improve how healthcare providers manage heart health in kidney patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged≥45 years (or ≥18 with a history of diabetes). b. Cases: Incident haemodialysis patients c. A comparative arm of peritoneal dialysis patients and CKD 3-4 (not on dialysis) with hypertension as a key risk factor for CVD.
• • d. Capable of understanding the purpose and risks of the study, fully informed, and given informed consent.
• Exclusion Criteria:
• • 1. Patients with pre-existing heart disease will be excluded.
• • 2. Patients with active cancer.